Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2011-07, Vol.25 (7), p.1197-1200
Hauptverfasser:	Kraljacic, B C, Arguello, M, Amri, A, Cormack, G, Borden, K
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/67/1059/602 692/699/67/1990/283/1897 692/700/565/1436/1437 Acute myeloid leukemia Aged Antineoplastic Combined Chemotherapy Protocols - pharmacology Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzenesulfonates - pharmacology Binding, Competitive Biological and medical sciences Cancer Cancer Research Chemotherapy Clinical Trials, Phase II as Topic Critical Care Medicine Cytarabine - pharmacology Drug Synergism Eukaryotic Initiation Factor-4E - antagonists & inhibitors Health aspects Hematologic and hematopoietic diseases Hematology Humans Idarubicin - pharmacology Indexing in process Initiation factor eIF-4E Intensive Internal Medicine letter-to-the-editor Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - pathology Leukemia, Myelomonocytic, Acute - drug therapy Leukemia, Myelomonocytic, Acute - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Medicine Medicine & Public Health Middle Aged Niacinamide - analogs & derivatives Oncology Phenylurea Compounds Pyridines - pharmacology Ribavirin Ribavirin - metabolism Ribavirin - pharmacology Ribavirin - therapeutic use RNA Caps - antagonists & inhibitors RNA Caps - metabolism Tumor Cells, Cultured - drug effects Tumor Stem Cell Assay
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2011.57